Calibre Scientific Acquires LINARIS Biologische Produkte to Expand Product Portfolio and Customer Reach in the DACH Region
LOS ANGELES, June 13, 2021 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of LINARIS Biologische Produkte GmbH (“LINARIS”), a life science distributor with headquarters outside of Frankfurt, Germany. LINARIS will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for customers in the DACH region.
LINARIS is a specialized distributor of a comprehensive product offering that includes antibodies, proteins, ELISA kits, and reagents from leading global manufacturers. For over 30 years, customers from top German universities, hospitals, research institutes, pathology labs, and pharma and biotech companies have trusted LINARIS to provide quality products coupled with knowledgeable technical support from their team.
With this acquisition, BIOZOL further enhances its leading position in the German research and diagnostics market, as LINARIS brings new supplier relationships and product expertise that complement BIOZOL’s current capabilities. “We are very excited about this acquisition,” said Jonas Bäuerle, Managing Director of BIOZOL. “With LINARIS, we will expand our catalogue of high-quality life science products and introduce them to our broad customer base, to further solidify our position as the premier independent distribution platform in the DACH region for the world’s leading manufacturers.”
Dr. Peter Harbarth, Managing Director & CEO of LINARIS added, “Calibre Scientific has built a unique platform in the life science and diagnostics space: with this transition, I have the utmost confidence that the company I founded three decades ago will be in good hands for decades to come. BIOZOL has deep expertise in our market, and I trust them to carry on my mission of providing excellent products and service to our customers.”
About Calibre Scientific
Calibre Scientific is a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics, industrial, and biopharmaceutical communities. Calibre Scientific owns a portfolio of 18 life science and diagnostic companies that have an unrivaled ability to address the unique challenges of their respective markets. Our global reach extends to over 100 countries, empowering customers all over the world. Headquartered in Los Angeles, California, Calibre Scientific continues to grow, further expanding its product offering and global footprint to laboratories across a wide array of verticals and geographies.
For more information, visit www.calibrescientific.com, or contact Brice Geoffrion, Director of Business Development, at bgeoffrion@calibrescientific.com, or +1 (310) 651-8285.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sodexo announces solid H1 Fiscal 2024 results19.4.2024 07:00:00 CEST | Press release
Issy-les-Moulineaux, April 19, 2024 Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo announces solid H1 Fiscal 2024 results Organic Revenue growth +8.5%Underlying operating profit +16.9% at constant currencies, margin up +40 bpsFiscal 2024 guidance:Organic growth now expected at the top of the +6% to +8% rangeUnderlying operating profit margin improvement confirmed at +30 to +40 bps, at constant currencies At the Board of Directors meeting held on April 18, 2024, chaired by Sophie Bellon, the Board closed the Consolidated accounts for the First half Fiscal 2024 ended February 29, 2024. First half Fiscal 2024 key figures (in million euros)H1 FISCAL 2024H1 FISCAL 2023 RESTATEDDIFFERENCEDIFFERENCE CONSTANT RATESRevenues12,10111,581 +4.5% +7.8%Organic revenue growth +8.5% +12.9%UNDERLYING OPERATING PROFIT612545+12.3%+16.9%UNDERLYING OPERATING PROFIT MARGIN5.1%4.7%+40bps+40bpsOther operating income & expenses30(36)OPERATING PROFIT642509+26.1%+30.1%Net financial expense(46)(43)Tax cha
Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth and Recurring EBITDA margin objectives19.4.2024 07:00:00 CEST | Press release
First Half Fiscal 2024 Results Issy-les-Moulineaux, France – April 19, 2024 First Half Fiscal 2024 highlights Successful spin-off and listing on Euronext Paris on February 1, 2024 Organic revenue growth of +24% incl. +26% in Q2, reflecting buoyant performance across all regions Strong Recurring EBITDA at €201 million, i.e. +28% organic growth; 34.4% margin at constant rates Net profit of €68 million reflecting higher one-time items, mostly spin-off related Recurring free cash flow of €228 million, with strong Recurring Cash conversion of 113%Net cash position of €1,065 million, increasing by €206 million since August 31, 2023Fiscal 2024 financial objectives raised: Organic revenue growth expected between 15% to 17% and Recurring EBITDA margin expected at 35% at least including standalone costs at constant rates, while reaffirming all mid-term targets First Half Fiscal 2024 key figures (in millions of euros)H1 FY 2024H1 FY 2023Variation (%)Variation at constant rate (%)Total revenues593
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer19.4.2024 07:00:00 CEST | Press release
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and on
Evs Invites Its Shareholders to the Ordinary General Meeting and an Extraordinary General Meeting on May 21, 202419.4.2024 06:30:00 CEST | Press release
Publication on April 19, 2024, at 6:30 am before market opening Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS INVITES ITS SHAREHOLDERS TO THE ORDINARY GENERAL MEETING AND AN EXTRAORDINARY GENERAL MEETING ON MAY 21, 2024 EVS Broadcast Equipment, leading provider of live video production systems, published today the invitation to its Ordinary General Meeting, to be held on May 21, 2024, at 11 am, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). Aside from the usual topics, including the 2023 annual and sustainability reports, the Board of Directors will propose to the Shareholders to approve the following resolutions: The payment of a total gross dividend of EUR 1.10 per share (including the interim dividend of EUR 0.50 paid in November 2023);A profit-sharing plan in the form of a grant of 36 EVS shares for each EVS employee, in proportion to
Icelandic Salmon - Annual Report for 202319.4.2024 06:00:00 CEST | Press release
Bíldudalur, 19 April 2023 Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) has today published its integrated Annual Report for 2023, including sustainability reporting and complete annual accounts with notes. The report is attached and available on the company‘s website: https://arnarlax.is/investors/ “In 2023, Icelandic Salmon supplied the world markets with a record-breaking 17,919 tonnes of salmon, thanks to the dedicated work of our employees. Despite facing many challenges this year - including macroeconomic changes, geopolitical tensions, and biological obstacles – we prioritised the health and wellbeing of our fish. Looking ahead, we are committed to sustaining this priority while growing our operations," Bjørn Hembre, CEO of Icelandic Salmon and Arnarlax says. In Bjørn‘s letter, which in included in the report, he writes: “Salmon farming holds great promise for Iceland, in terms of future jobs and economic growth. During the past few years, we have see